Onkológia 1/2018

Nivolumab in the renal cell carcinoma treatment

This review is focused on position of nivolumab in renal cell carcinoma (RCC) treatment. The introductory part provides a brief overview of the systemic therapy options for inoperable advanced or metastatic clear-cell RCC and it explains the checkpoint inhibitors mechanism of action. The core of the article presents the study with nivolumab monotherapy following progression on tyrosine kinase inhibitors (in its context, the author intends to select the optimal therapeutic alternative in the clinical practice) and the study comparing the firstline combination of nivolumab and ipilimumab with sunitinib in untreated patients with metastatic RCC. The last part of the article is an overview of selected ongoing studies with nivolumab.

Keywords: renal cell carcinoma, nivolumab, cabozantinib, ipilimumab